Search

Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients

HBA Rising Star & Luminary Awards | Boehringer Ingelheim US

Read more on the HBA, is a global nonprofit organization recognizing outstanding individuals and companies who impact and influence women in healthcare.

Jardiance® (empagliflozin) Meets Endpoint Reducing CV Death | BI US

BI announces results from the EMPEROR-Reduced trial with heart failure with reduced ejection fraction, with & without diabetes. View ISI, PI and Med Guide.

Real-world data announced for adults with type 2 diabetes

Two analyses of the U.S. data from the EMPRISE real-world study show that Jardiance (empagliflozin) tablets was associated with a reduction in risk of hospitalization for heart failure compared with two other classes of glucose-lowering therapies in adult

Bringing focus to unmet needs in biliary tract and pancreatic cancer with the Brightline-2 Trial

Brightline-2 clinical trial is studying our investigational MDM2-p53 antagonist for people with advanced cancer in the biliary tract or pancreatic cancer.

2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic

Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease

Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease

Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

New Documentary Highlights Ranch’s Commitment to Cattle Health

Full data announced in DINAMO trial in young people with T2D

Jardiance (empagliflozin) tablets is the first SGLT2 inhibitor to show statistically significant

Taking patient centricity to new heights

Learn about how we focus on putting patients first and finding solutions to meet their healthcare needs.

Saving Stroke Patients around the world

Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. Over 15 million people worldwide suffer a stroke every year.

U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes

FDA Mini-Sentinel Assessment Reinforces Safety Data of Pradaxa® (dabigatran etexilate mesylate)

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism

Cancer

Advocating for More Patient-Centered Mental Health Care

Supply Chain Scholarship for Cowtribe

A supply chain course we sponsored boosted the career of Latifa Saaka

Sustainable cattle production: Feeding the world while minimizing environmental effect

FDA approves the first treatment option for generalized pustular psoriasis flares in adults

FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)

FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children

New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline

Diversity

At Boeheringer Ingelheim, we believe in a diverse working culture. Find out what our people like most about working with us.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients

HBA Rising Star & Luminary Awards | Boehringer Ingelheim US

Jardiance® (empagliflozin) Meets Endpoint Reducing CV Death | BI US

Real-world data announced for adults with type 2 diabetes

Bringing focus to unmet needs in biliary tract and pancreatic cancer with the Brightline-2 Trial

2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic

Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease

Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

New Documentary Highlights Ranch’s Commitment to Cattle Health

Full data announced in DINAMO trial in young people with T2D

Taking patient centricity to new heights

Saving Stroke Patients around the world

U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes

FDA Mini-Sentinel Assessment Reinforces Safety Data of Pradaxa® (dabigatran etexilate mesylate)

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism

Cancer

Advocating for More Patient-Centered Mental Health Care

Supply Chain Scholarship for Cowtribe

Sustainable cattle production: Feeding the world while minimizing environmental effect

FDA approves the first treatment option for generalized pustular psoriasis flares in adults

FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)

FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children

New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline

Diversity